Roivant Q4 net loss widens to $206.5M; brepocitinib DM readout on track for H2 2025

Roivant Sciences Ltd.

2024-FY EPS reported -$0.24 revenue$29,053,000

Net loss attributable to Roivant of $206.5M ($0.29 loss per share) for Q4 FY2025, vs $151.1M loss ($0.19) a year ago.
Revenue of $7.6M, down 16% YoY; R&D expenses rose 35% to $145.2M.
Consolidated cash, equivalents, restricted cash and marketable securities of $4.9B at March 31, 2025.
Repurchased $1.3B of shares, reducing outstanding shares by 14% from March 31, 2024.
Brepocitinib Phase 3 in dermatomyositis fully enrolled; topline data expected H2 2025; NIU Phase 3 enrolling.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.